104 related articles for article (PubMed ID: 38949195)
1. A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.
Sun ALA; Gillies JD; Shen Y; Deng H; Xue F; Ma Y; Song L
Clin Transl Sci; 2024 Jul; 17(7):e13857. PubMed ID: 38949195
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.
Hincelin-Mery A; Nicolas X; Cantalloube C; Pomponio R; Lewanczyk P; Benamor M; Ofengeim D; Krupka E; Hsiao-Nakamoto J; Eastenson A; Atassi N
Clin Transl Sci; 2024 Jan; 17(1):e13690. PubMed ID: 38010108
[TBL] [Abstract][Full Text] [Related]
4. A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.
Lickliter J; Wang S; Zhang W; Zhu H; Wang J; Zhao C; Shen H; Wang Y
Clin Transl Sci; 2023 Sep; 16(9):1691-1703. PubMed ID: 37345561
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
6. A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.
Jones NS; Kshirsagar S; Mohanan V; Ramakrishnan V; Di Nucci F; Ma L; Mao J; Ding H; Klabunde S; Vucic D; Pan L; Lekkerkerker AN; Chen Y; Rothenberg ME
Clin Transl Sci; 2023 Oct; 16(10):1997-2009. PubMed ID: 37596814
[TBL] [Abstract][Full Text] [Related]
7. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers.
Grievink HW; Heuberger JAAC; Huang F; Chaudhary R; Birkhoff WAJ; Tonn GR; Mosesova S; Erickson R; Moerland M; Haddick PCG; Scearce-Levie K; Ho C; Groeneveld GJ
Clin Pharmacol Ther; 2020 Feb; 107(2):406-414. PubMed ID: 31437302
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Esfandiari E; Chen M; Smithson G; Blair D; Faessel H; Wagner J; Mclean L; Fedyk ER
Clin Transl Sci; 2021 May; 14(3):820-828. PubMed ID: 33650758
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
[TBL] [Abstract][Full Text] [Related]
11. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP; Pradhan V; Roberts ES; Scaramozza M; Kieras E; Gale JD; Peeva E; Vincent MS; Banerjee A; Fensome A; Dowty ME; Winkle P; Tehlirian C
Clin Transl Sci; 2021 Mar; 14(2):671-682. PubMed ID: 33290616
[TBL] [Abstract][Full Text] [Related]
12. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM; Heuberger JAAC; Groeneveld GJ; Oude Nijhuis J; De Deyn PP; Hadi S; Harris J; Tsai RM; Cruz-Herranz A; Huang F; Tong V; Erickson R; Zhu Y; Scearce-Levie K; Hsiao-Nakamoto J; Tang X; Chang M; Fox BM; Estrada AA; Pomponio RJ; Alonso-Alonso M; Zilberstein M; Atassi N; Troyer MD; Ho C
Clin Transl Sci; 2022 Aug; 15(8):2010-2023. PubMed ID: 35649245
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
Shi JG; Chen X; Lee F; Emm T; Scherle PA; Lo Y; Punwani N; Williams WV; Yeleswaram S
J Clin Pharmacol; 2014 Dec; 54(12):1354-61. PubMed ID: 24965573
[TBL] [Abstract][Full Text] [Related]
15. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
17. Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
Weisel K; Berger S; Papp K; Maari C; Krueger JG; Scott N; Tompson D; Wang S; Simeoni M; Bertin J; Peter Tak P
Clin Pharmacol Ther; 2020 Oct; 108(4):808-816. PubMed ID: 32301501
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.
Lee SK; Xing J; Catlett IM; Adamczyk R; Griffies A; Liu A; Murthy B; Nowak M
Eur J Clin Pharmacol; 2017 Jun; 73(6):689-698. PubMed ID: 28265691
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Smith PF; Krishnarajah J; Nunn PA; Hill RJ; Karr D; Tam D; Masjedizadeh M; Funk JO; Gourlay SG
Br J Clin Pharmacol; 2017 Nov; 83(11):2367-2376. PubMed ID: 28636208
[TBL] [Abstract][Full Text] [Related]
20. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
